CLAIMS

WHAT IS CLAIMED IS:

1. A formulation that comprises from 1 mg/ml to 150 mg/ml of an anti-CD105 antibody, or antigen-binding fragment thereof, from 10 to 20 mM of a buffering agent, up to 240 mM of a polyol, and a pH of from 5.3 to 5.7; wherein the buffering agent comprises histidine, and wherein the polyol comprises trehalose or sorbitol.

2. The formulation of claim 1, that comprises 240 mM trehalose.

3. The formulation of claim 1, that comprises 240 mM sorbitol.

4. The formulation of claim 1, that comprises 10 mM histidine.

5. The formulation of claim 1, that comprises 20 mM histidine.

6. The formulation of claim 1, that further comprises a surfactant.

7. The formulation of claim 6, wherein the surfactant comprises polysorbate 20, polysorbate 80 or PLURONIC® F68.

8. The formulation of claim 1, wherein the pH is 5.3, 5.4, 5.5, 5.6, or 5.7.

9. The formulation of claim 1, wherein the pH is from 5.4 to 5.6.

10. The formulation of claim 1 that comprises from 25 mg/ml to 100 mg/ml of the anti-CD105 antibody, or antigen-binding fragment thereof.

11. The formulation of claim 1 that comprises 25 mg/ml of the anti-CD105 antibody, or antigen-binding fragment thereof.

12. The formulation of claim 1 that comprises 50 mg/ml of the anti-CD105 antibody, or antigen-binding fragment thereof.

13. The formulation of claim 1 that comprises 100 mg/ml of the anti-CD105 antibody, or antigen-binding fragment thereof.

14. A pre-filled syringe suitable for intravenous administration comprising the formulation of any one of claims 1-13.

15. A pre-filled syringe suitable for intravitreal administration comprising a formulation of any one of claims 1-13.

16. Use of a formulation of any one of claims 1-13, in the manufacture of a medicament for the treatment of an angiogenesis-related disease in a subject in need thereof.

17. The use of claim 16, wherein the formulation is to be administered intravitreally.

18. The use of claim 16, wherein the formulation is to be administered intravenously.

19. The use of claim 16, wherein the angiogenesis-related disease comprises a cancer or a metastasis thereof.

20. The use of claim 19, wherein the cancer or the metastasis thereof comprises a solid tumor.

21. The use of claim 19, wherein the cancer or the metastasis thereof comprises a lung cancer, a melanoma, a breast cancer, a pancreatic cancer, an ovarian cancer, a colorectal cancer, a prostate cancer, a kidney cancer, a liver cancer, a uterine cancer, a neck cancer, a sarcoma, a myeloma, a brain cancer, or a lymphoma.

22. The use of claim 21, wherein the cancer or the metastasis thereof comprises the sarcoma and the sarcoma comprises an angiosarcoma.

23. The use of claim 16, wherein the angiogenesis-related disease comprises an ophthalmologic condition.

24. The use of claim 23, wherein the ophthalmologic condition comprises age-related macular degeneration, diabetic retinopathy, or choroidal neovascularization.

25. The use of claim 24, wherein the ophthalmologic condition comprises age-related macular degeneration, and the age-related macular degeneration (AMD) comprises wet AMD or dry AMD.

26. The use of claim 16, wherein the formulation is to be administered to the subject one or more times.

27. The use of claim 16, wherein the formulation is to be administered to the subject once per day, once per week, once per month, once bi-monthly, once every two months, once every three months, once every four months, once every 5 months, or once every 6 months.

28. A formulation that comprises from 1 mg/ml to 150 mg/ml of an anti-CD105 antibody, or antigen-binding fragment thereof, from 10 to 20 mM of a buffering agent, up to 240 mM of a polyol, and a pH of from 3.8 to 4.2; wherein the buffering agent comprises acetate, and wherein the polyol comprises trehalose or sorbitol.

29. The formulation of claim 28, that comprises 240 mM trehalose.

30. The formulation of claim 28, that comprises 240 mM sorbitol.

31. The formulation of claim 28, that comprises 10 mM histidine.

32. The formulation of claim 28, that comprises 20 mM histidine.

33. The formulation of claim 28, that further comprises a surfactant.

34. The formulation of claim 33, wherein the surfactant comprises polysorbate 20, polysorbate 80 or PLURONIC® F68.

35. The formulation of claim 28, wherein the pH is 3.8, 3.9, 4.0, 4.1, or 4.2.

36. The formulation of claim 28, wherein the pH is from 3.9 to 4.1.

37. The formulation of claim 28 that comprises from 25 mg/ml to 100 mg/ml of the anti-CD105 antibody, or antigen-binding fragment thereof.

38. The formulation of claim 28 that comprises 25 mg/ml of the anti-CD105 antibody, or antigen-binding fragment thereof.

39. The formulation of claim 28 that comprises 50 mg/ml of the anti-CD105 antibody, or antigen-binding fragment thereof.

40. The formulation of claim 28 that comprises 100 mg/ml of the anti-CD105 antibody, or antigen-binding fragment thereof.

41. A pre-filled syringe suitable for intravenous administration comprising the formulation of any of claims 28-40.

42. A pre-filled syringe suitable for intravitreal administration comprising a formulation of any one of claims 28-40.

43. Use of a formulation of any one of claims 28-40, in the manufacture of a medicament for the treatment of an angiogenesis-related disease in a subject in need thereof.

44. The use of claim 43, wherein the formulation is to be administered intravitreally.

45. The use of claim 43, wherein the formulation is to be administered intravenously.

46. The use of claim 43, wherein the angiogenesis-related disease comprises a cancer or a metastasis thereof.

47. The use of claim 46, wherein the cancer or the metastasis thereof comprises a solid tumor.

48. The use of claim 46, wherein the cancer or the metastasis thereof comprises a lung cancer, a melanoma, a breast cancer, a pancreatic cancer, an ovarian cancer, a colorectal cancer, a prostate cancer, a kidney cancer, a liver cancer, a uterine cancer, a neck cancer, a sarcoma, a myeloma, a brain cancer, or a lymphoma.

49. The use of claim 48, wherein the cancer or the metastasis thereof comprises the sarcoma and the sarcoma comprises an angiosarcoma.

50. The use of claim 43, wherein the angiogenesis-related disease comprises an ophthalmologic condition.

51. The use of claim 50, wherein the ophthalmologic condition comprises age-related macular degeneration, diabetic retinopathy, or choroidal neovascularization.

52. The use of claim 51, wherein the ophthalmologic condition comprises age-related macular degeneration, and the age-related macular degeneration (AMD) comprises wet AMD or dry AMD.

53. The use of claim 43, wherein the formulation is to be administered to the subject one or more times.

54. The use of claim 43, wherein the formulation is to be administered to the subject once per day, once per week, once per month, once bi-monthly, once every two months, once every three months, once every four months, once every 5 months, or once every 6 months.